维多珠单抗皮下制剂维持治疗溃疡性结肠炎的随机试验
这项3期双盲双模拟试验在29国141中心纳入216例中重度活动性溃疡性结肠炎患者,静脉维多珠单抗诱导后随机接受皮下、静脉维多珠单抗或安慰剂维持。第52周临床缓解率皮下组46.2%、静脉组42.6%、安慰剂组14.3%(皮下vs安慰剂Δ32.3%,95%CI 19.7%-45.0%,P<.001)。皮下组注射部位反应10.4%,高于静脉组1.9%和安慰剂组0%,多为轻度且未导致停药。
要点
- 皮下维多珠单抗108mg每2周维持治疗第52周临床缓解率46.2%,安慰剂14.3%。
- 皮下组内镜改善和持久临床缓解均优于安慰剂(均P<.001)。
- 注射部位反应皮下组10.4%,静脉组1.9%,安慰剂0%,多为轻度未致停药。
核心结论
- 皮下维多珠单抗对静脉诱导有临床应答的中重度活动性溃疡性结肠炎患者是有效的维持治疗,安全性和耐受性良好。
研究设计与样本
- 患者先开放标签接受静脉维多珠单抗300mg第0和2周诱导,第6周有临床应答者随机接受皮下维多珠单抗108mg每2周、静脉维多珠单抗300mg每8周或安慰剂维持,共216例随机。
- 主要终点为第52周临床缓解,定义为Mayo总分≤2且无单项评分>1。
主要发现
- 第52周临床缓解率:皮下维多珠单抗组46.2% vs 静脉维多珠单抗组42.6% vs 安慰剂组14.3%(皮下vs安慰剂Δ32.3%,95%CI 19.7%-45.0%,P<.001)。
- 皮下维多珠单抗组第52周内镜改善和持久临床应答均优于安慰剂(均P<.001)。
- 注射部位反应发生率皮下维多珠单抗组10.4%,静脉维多珠单抗组1.9%,安慰剂组0%;均非治疗限制性,多为轻度,无一导致停药。
- 皮下与静脉维多珠单抗的其他安全性特征相似。
关键数值与推荐
- 临床缓解定义:Mayo总分≤2且无单项评分>1。
- 皮下维多珠单抗剂量108mg每2周;静脉维多珠单抗剂量300mg每8周。
临床怎么用
- 对静脉维多珠单抗诱导有临床应答的中重度活动性溃疡性结肠炎患者,皮下维多珠单抗108mg每2周可作为维持治疗选择。
- 皮下维多珠单抗注射部位反应较静脉制剂常见,但多为轻度且未导致停药。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Maintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously. Some patients might prefer a subcutaneous formulation of vedolizumab for maintenance treatment. Subcutaneous vedolizumab was investigated as maintenance treatment in patients with moderately to severely active ulcerative colitis. METHODS: We performed a phase 3, double-blind, double-dummy trial at 141 sites in 29 countries from December 18, 2015 through August 21, 2018. Patients with moderately to severely active ulcerative colitis received open-label treatment with intravenous vedolizumab 300 mg at weeks 0 and 2. At week 6, patients with clinical response were randomly assigned maintenance treatment with subcutaneous vedolizumab 108 mg every 2 weeks, intravenous vedolizumab 300 mg every 8 weeks, or placebo. The primary end point was clinical remission at week 52, which was defined as a total Mayo score of ≤2 and no subscore >1. RESULTS: Among the randomized 216 patients, clinical remission at week 52 was achieved by 46.2%, 42.6%, and 14.3% of patients in the subcutaneous vedolizumab, intravenous vedolizumab, and placebo groups, respectively (subcutaneous vedolizumab vs placebo: Δ32.3%; 95% confidence interval, 19.7%-45.0%; P < .001). The subcutaneous vedolizumab group also had greater endoscopic improvement and durable clinical response at week 52 compared with placebo (both P < .001). The incidence of injection-site reactions was more frequent in patients given subcutaneous vedolizumab (10.4%) than intravenous vedolizumab (1.9%) or placebo (0%); these were not treatment limiting, most were mild, and none resulted in discontinuation. Subcutaneous and intravenous vedolizumab safety profiles were otherwise similar. CONCLUSIONS: Subcutaneous vedolizumab is effective as maintenance therapy in patients with moderately to severely active ulcerative colitis who had a clinical response to intravenous vedolizumab induction therapy. It has a favorable safety and tolerability profile. ClinicalTrials.gov ID: NCT02611830; EudraCT 2015-000480-14.
引用
- Sandborn WJ, Baert F, Danese S, et al. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2019. PMID: 31470005. doi:10.1053/j.gastro.2019.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。